Regeneron Pharmaceuticals, Inc. (REGN) Wins FDA Approval for Livsayis in gMG
Regeneron (REGN) received FDA approval for Livsayis, a treatment for AChR-positive generalized myasthenia gravis. It is the first siRNA therapy and only gMG treatment dosed subcutaneously four times a year. The approval marks an early commercial milestone for Regeneron's first approved siRNA therapy and neurology medicine. The EU regulatory decision is expected in the second half of 2027.
How this was made

The 30-second read
Why it matters
The approval could add a multi‑billion‑dollar revenue stream over the next decade if uptake meets expectations.
Market read
Regeneron's stock is expected to react positively to the FDA approval, with broader implications for RNA‑based therapeutics.
What to watch
Potential pricing pressure from insurers and the need for post‑approval real‑world data
Background
Regeneron announced its first siRNA therapy for a neurology indication, expanding beyond its antibody portfolio.
Ticker impact
FDA approved Regeneron's siRNA therapy Livsayis for adult AChR‑positive generalized myasthenia gravis.
likely upward pressure as investors price in new revenue potential
First FDA‑approved siRNA for gMG, limited competition and quarterly dosing could drive strong uptake.
Market effects
strengthens the biotech/siRNA sector and may boost peers developing RNA‑based therapies
U.S. biotech market gains from a high‑profile FDA approval
sets a precedent for siRNA treatments in autoimmune diseases worldwide
Counterpoint
Market may have already priced in the approval; execution risk and reimbursement uncertainty could limit upside
Key entities
- companyRegeneron Pharmaceuticals, Inc.
US‑listed biotech firm developing Livsayis
- regulatory_bodyFDA
U.S. Food and Drug Administration granting approval



